Multiple sclerosis affects roughly 2.8 million people worldwide, and the pace of therapeutic innovation over the past decade has fundamentally altered what neurologists and patients can expect from long-term disease management. A comprehensive review in the New England Journal of Medicine arrives at a moment when the field is grappling with how to sequence increasingly potent therapies and whether earlier, more aggressive intervention can meaningfully alter the disease's trajectory before irreversible neurodegeneration takes hold.
The review, published in NEJM's July 2026 issue, synthesizes the current understanding of MS pathophysiology, disease-modifying therapy categories, and emerging treatment targets. It addresses the spectrum from relapsing-remitting to progressive forms, highlighting advances in B-cell depleting agents, BTK inhibitors under investigation, and the growing evidence for high-efficacy therapies deployed early rather than reserved for refractory cases. Biomarkers such as serum neurofilament light chain (sNfL) receive attention as objective measures of neuroaxonal injury that are increasingly informing treatment decisions and trial endpoints.
For health-conscious adults and those with family histories of autoimmune disease, this review signals several important shifts. First, MS is no longer uniformly progressive in the traditional sense — treatment can substantially suppress relapse rates and slow brain volume loss. Second, the field is converging on a treat-to-target philosophy analogous to oncology or cardiovascular medicine, where waiting for clinical failure before escalating therapy may cost patients irreplaceable neurological reserve. Third, remyelination strategies — long considered aspirational — are now entering serious clinical investigation.
Key limitations of the current evidence base include underrepresentation of progressive MS subtypes in landmark trials and the challenge of long follow-up needed to measure true neuroprotection. As a review article rather than primary research, this piece synthesizes rather than generates new data, but its NEJM platform and scope make it an authoritative benchmark for where MS care stands heading into the latter 2020s.